[{"AccountsPayableCurrent_0_Q2_USD":950000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":335000.0,"MarketableSecuritiesCurrent_0_Q2_USD":138888000.0,"ProceedsFromSaleOfProductiveAssets_2_Q2_USD":20000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":10396000.0,"ProceedsFromIssuanceOfDebt_2_Q2_USD":2962000.0,"IncreaseDecreaseInAccountsAndOtherReceivables_2_Q2_USD":-686000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":722000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1408000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":45190000.0,"OtherLiabilitiesCurrent_0_Q2_USD":2104000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":47000000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q2_USD":329000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":722000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":7.96,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-3000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-25000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":20000.0,"OtherLiabilities_0_Q2_USD":12500000.0,"StockIssuedDuringPeriodValueOther_1_Q2_USD":23692000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-11031000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-23656000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":2313000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-11034000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-23681000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1272783000.0,"OtherAssetsNoncurrent_0_Q2_USD":41000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":7.95,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-11031000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":138891000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":13000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_Q2_pure":0.91,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_Q2_pure":0.97,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":236000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2965000.0,"RepaymentsOfDebt_2_Q2_USD":2962000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2_Q2_USD":0.0,"ProceedsFromStockPlans_2_Q2_USD":24000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":132439000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q2_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":3134000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":1720000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1320000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":10000.0,"InvestmentsAndCash_0_Q2_USD":206900000.0,"IncreaseDecreaseInEquitySecuritiesFvNi_2_Q2_USD":0.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1_Q2_USD":3500000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2_Q2_USD":3500000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q2_USD":0.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":100000.0,"ContractWithCustomerLiability_0_Q2_USD":303000.0,"ContractWithCustomerAssetNet_0_Q2_USD":0.0,"ConstructionInProgressExpendituresIncurredButNotYetPaid_2_Q2_USD":22000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":56795000.0,"BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0_Q2_USD":107500000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_1_Q2_USD":5132000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_2_Q2_USD":4898000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q2_USD":45200000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_Q2_pure":0.006,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-23656000.0,"BusinessCombinationContingentConsiderationLiability_0_Q2_USD":7587000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":1145000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-23332000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-86564000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":166691000.0,"LiabilitiesCurrent_0_Q2_USD":10841000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":261401000.0,"Liabilities_0_Q2_USD":22957000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":436000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-228000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-228000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-11259000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-23884000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":1748000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":3528000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.5,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.2,"CostsAndExpenses_1_Q2_USD":11601000.0,"CostsAndExpenses_2_Q2_USD":27196000.0,"CommonStockValue_0_Q2_USD":39000.0,"CommonStockSharesOutstanding_0_Q2_shares":39093868.0,"CommonStockSharesIssued_0_Q2_shares":39093868.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":68027000.0,"AssetsCurrent_0_Q2_USD":208992000.0,"Assets_0_Q2_USD":261401000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":3085287.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":2594000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":7194000.0,"DeferredTaxLiabilities_0_Q2_USD":2779000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":166667000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1036972000.0,"InterestReceivable_0_Q2_USD":200000.0,"InterestAndOtherIncome_1_Q2_USD":106000.0,"InterestAndOtherIncome_2_Q2_USD":347000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-1412000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-254000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q2_pure":0.005,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q2_pure":0.97,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q2_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensation_2_Q2_USD":1408000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":9705000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":21400000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":4044000.0,"PreferredStockValue_0_Q2_USD":null,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":3000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.01,"OperatingIncomeLoss_1_Q2_USD":-11365000.0,"OperatingIncomeLoss_2_Q2_USD":-24231000.0,"CommonStockSharesAuthorized_0_Q2_shares":297000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":6467000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":22082000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":19744000.0,"StockholdersEquity_0_Q2_USD":238444000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_Q2_pure":0.005,"Ticker":"CLDX","CIK":"744218","name":"CELLDEX THERAPEUTICS, INC.","OfficialName":"Celldex Therapeutics Inc.","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1601609341.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]